Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is a Healthcare company (Biotechnology) with a market capitalization of $3.1B. The Maz Rating grades it against the other companies in its sector.
Xeris Biopharma Holdings, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.80, Xeris Biopharma Holdings, Inc. trades at 8.3x sales and 61.9x book value, with an EV/EBITDA of 120.4. Over the last twelve months it generated about $371M of revenue and a net loss of $7M. It runs a gross margin of 84.4%, an operating margin of 12.7% and a net margin of -1.8%. It shows return on equity of -39.5%, return on invested capital of 15.9% and a free cash flow yield of 2.4%. On the balance sheet: a debt-to-equity ratio of 4.63 and a current ratio of 2.15. Over the past 52 weeks the share price ranged from $5.25 to $16.98, with a beta of 0.84.
Xeris Biopharma Holdings, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 10 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Xeris Biopharma Holdings, Inc. (XERS) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 10.6% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.33% / 30% · Interest income / Revenue 0.77% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 10.6% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.33% / 33% · Receivables / Mkt Cap (36m) 3.84% / 49% · Interest income / Revenue 0.77% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 10.6% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.33% / 33.33% · Receivables / Mkt Cap (24m) 3.84% / 33.33% · Interest income / Revenue 0.77% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 32.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 29.5% / 33.33% · Receivables / Avg Assets (4Q) 14.5% / 33.33% · Interest income / Revenue 0.77% / 5% | Pass |
| FTSE | Debt / Total Assets 44.8% / 33.33% · (Cash+ST Inv) / Total Assets 31.0% / 33.33% · (Cash+Recv) / Total Assets 47.2% / 33.33% · Interest income / Revenue 0.77% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Xeris Biopharma Holdings, Inc. (XERS) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Xeris Biopharma Holdings, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.77% of each dividend: Xeris Biopharma Holdings, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.